Skip to main content
. 2018 Feb 4;9(36):24237–24247. doi: 10.18632/oncotarget.24386

Figure 7. Kaplan-Meier survival curves of progression-free survival in patients who received afatinib doses of 30 mg and 40 mg.

Figure 7